StockNews.com Begins Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report released on Friday. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Mizuho decreased their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $2.18.

Adaptimmune Therapeutics Stock Up 3.9 %

Adaptimmune Therapeutics stock opened at $0.29 on Friday. The company has a market capitalization of $74.41 million, a P/E ratio of -1.32 and a beta of 2.52. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.65. The stock has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $0.69.

Institutional Trading of Adaptimmune Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ADAP. GSA Capital Partners LLP acquired a new stake in shares of Adaptimmune Therapeutics during the third quarter worth $95,000. FMR LLC boosted its holdings in Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Jane Street Group LLC increased its position in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the period. Virtu Financial LLC raised its stake in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after buying an additional 21,769 shares in the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 94,623 shares in the last quarter. 31.37% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.